John Landry
Eli Lilly (United States)(US)Eli Lilly (Canada)(CA)
Publications by Year
Research Areas
Schizophrenia research and treatment, Bipolar Disorder and Treatment, Treatment of Major Depression, Electroconvulsive Therapy Studies, Diabetes Treatment and Management
Most-Cited Works
- → Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease(2019)194 cited
- → Olanzapine/Fluoxetine Combination in Children and Adolescents With Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Trial(2014)133 cited
- → Older Adults' Acceptance of Psychological and Pharmacological Treatments for Depression(2001)119 cited
- → A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy(2017)73 cited
- → Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials(2019)71 cited
- → Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide(2021)57 cited
- → Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder(2014)52 cited
- → A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti‐hyperglycaemic medication: results of the PARADIGM study(2012)39 cited
- → A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study(2009)34 cited
- → Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration(2020)34 cited